Indeed, dual targeting of MYC and JUNB by MZ-1 and siJUNB- or shJUNB-mediated knockdown, or the orally available MEK1/2- inhibitor trametinib, demonstrated synergistic anti-MM activity in various MM cell line cells, including MZ-1-resistant RPMI8226 cells [58]. This evidence concerns the gene MAP2K1 and Miyoshi myopathy.